Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP – Free Report) – Research analysts at HC Wainwright issued their FY2027 earnings per share estimates for shares of Neuphoria Therapeutics Inc. – Common Stock in a note issued to investors on Tuesday, February 4th. HC Wainwright analyst J. Pantginis expects that the company will earn ($1.21) per share for the year. HC Wainwright currently has a “Buy” rating and a $21.00 price objective on the stock. HC Wainwright also issued estimates for Neuphoria Therapeutics Inc. – Common Stock’s FY2028 earnings at ($1.36) EPS.
Neuphoria Therapeutics Inc. – Common Stock Stock Performance
NEUP stock opened at $5.15 on Wednesday. Neuphoria Therapeutics Inc. – Common Stock has a 1-year low of $2.12 and a 1-year high of $16.08.
About Neuphoria Therapeutics Inc. – Common Stock
Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
See Also
- Five stocks we like better than Neuphoria Therapeutics Inc. – Common Stock
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- 3 Must-Have ETFs Set to Dominate This Quarter
- There Are Different Types of Stock To Invest In
- Seeking Stability? These 3 Stocks Offer Strong Potential
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for Neuphoria Therapeutics Inc. - Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics Inc. - Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
